Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms) Publisher



Ghajarzadeh M1, 2 ; Mirmosayyeb O3 ; Molazadeh NM1 ; Sahraian MA1 ; Bonavita S4 ; Shaygannejad V5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy
  5. 5. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: International Journal of Preventive Medicine Published:2022


Abstract

Background: Patients with multiple sclerosis (MS) are considered at higher risk of COVID-19 infection due to treatment with immune modulators and immune-suppressive agents. The exact risk factors are not clear. So, we aimed to conduct a study to determine the predictors of catching COVID-19 infection during the pandemic stage in patients with multiple sclerosis (MS). Methods: We conducted a multicenter screening study and developed an online questionnaire to collect patients' self-reported demographic features along with MS-related and COVID-19-related information. The online questionnaire link was released by the Iran Multiple Sclerosis Society (IMSS) social media channel, accessible for 4160 MS patients totally and also was sent by WhatsApp for nonmember cases. Results: Totally, 1448 MS patients participated in our study. Twenty-five (1.7%) patients were diagnosed with COVID-19, from which 4 were hospitalized, 4 were treated with medical therapy, and 17 patients had home-quarantine. The patients with COVID-19 diagnosis were more frequently treated with rituximab (28% vs 24%, P = 0.001) than others, and cardiovascular comorbidity was more frequent in this group (8% vs 1.6%, P = 0.01). Regression analysis showed that cardiovascular disease was a significant positive predictor of COVID-19 infection (OR = 5.2, 95% CI: 1.1-23.7). Conclusions: Patients with MS who have cardiovascular disease should be more monitored for COVID-19 infection as they are at higher risk of infection. © 2022 Acoustical Society of America. All rights reserved.
Related Docs
View other Related Docs
1. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic, Biomolecules (2021)
2. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
3. Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021, Multiple Sclerosis and Related Disorders (2022)
4. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
5. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)
6. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
7. Assessment of Mental Health, Knowledge, and Attitude of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Response to 2019 Novel Coronavirus, Neurological Sciences (2021)
8. A Multi-Centre Longitudinal Study Analysing Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns During the Covid-19 Pandemic, Journal of Neurology (2024)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (67)
Masoud Etemadifar (51)
Other Related Docs
9. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
10. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
11. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
12. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
13. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
14. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
15. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
16. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
17. Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran, Vaccines (2022)
18. Favorable Outcome After Covid-19 Infection in a Multiple Sclerosis Patient Initiated on Ocrelizumab During the Pandemic, Multiple Sclerosis and Related Disorders (2020)
19. Covid-19 Susceptibility and Outcomes Among Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
20. Impact of the Covid-19 Pandemic on the Psychological Status and Cortisol Level of Multiple Sclerosis Patients, Neuropsychological Rehabilitation (2023)
21. Clinical Display, Diagnostics and Genetic Implication of Novel Coronavirus (Covid-19) Epidemic, European Review for Medical and Pharmacological Sciences (2020)
22. The Outcomes of Covid-19 Epidemic Crisis on the Elderly: A Review Study, Journal of Isfahan Medical School (2021)
23. Prevalence of Multiple Sclerosis (Ms) in Iran: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
24. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
25. Does Covid-19 Increase the Long-Term Relapsing-Remitting Multiple Sclerosis Clinical Activity? a Cohort Study, BMC Neurology (2022)
26. Fear and Anxiety in Patients With Multiple Sclerosis During Covid-19 Pandemic; Report of an Iranian Population, Multiple Sclerosis and Related Disorders (2021)
27. Characteristics of Covid-19 Disease in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
28. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
29. Can Coronavirus Disease 2019 (Covid-19) Trigger Exacerbation of Multiple Sclerosis? a Retrospective Study, Multiple Sclerosis and Related Disorders (2021)
30. Investigating the Effects of Covid-19 Prevalence on Demographic Variables and Its Relationship With Social Participation, Health in Emergencies and Disasters Quarterly (2023)
31. Multiple Sclerosis Disease-Modifying Therapies and Covid-19 Vaccines: A Practical Review and Meta-Analysis, Journal of Neurology, Neurosurgery and Psychiatry (2022)
32. Fear of Relapse, Social Support, and Psychological Well-Being (Depression, Anxiety, and Stress Level) of Patients With Multiple Sclerosis (Ms) During the Covid-19 Pandemic Stage, Neurological Sciences (2021)
33. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
34. A Narrative Review of Covid-19: The New Pandemic Disease, Iranian Journal of Medical Sciences (2020)
35. Telerehabilitation in People With Multiple Sclerosis: A Scoping Review, Journal of Modern Rehabilitation (2023)
36. Topics and Users' Emotions on Social Media Regarding the Covid-19 Vaccine: A Systematic Review, Ethiopian Medical Journal (2023)
37. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study, Neurology (2022)
38. Computerized Cognitive Rehabilitation in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2025)
39. Prognostic Value of Intrathecal Igg Synthesis in Multiple Sclerosis: A Study in 54 Patients, Tehran University Medical Journal (2008)
40. Neuro-Mucormycosis: Lessons From Covid-19-Associated Cases, Current Journal of Neurology (2023)
41. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
42. Comprehensive Overview of Covid-19-Related Respiratory Failure: Focus on Cellular Interactions, Cellular and Molecular Biology Letters (2022)
43. A Narrative Literature Review on Traditional Medicine Options for Treatment of Corona Virus Disease 2019 (Covid-19), Complementary Therapies in Clinical Practice (2020)
44. Comparing Body Image in Ms Patients and Healthy Individuals, International Journal of Body, Mind and Culture (2020)
45. Adjuvant Pomegranate Juice Intake Improves the Inflammatory Status of Hospitalized Covid-19 Patients: A Randomized and Placebo-Controlled Trial, Complementary Therapies in Medicine (2023)
46. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
47. Th1, Th2 and Th17 Cytokine Profile in Patients With Multiple Sclerosis Following Treatment With Rapamycin, Iranian Journal of Immunology (2016)
48. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
49. Cerebellitis Following Covid-19 Infection: A Case-Based Systematic Review and Pooled Analysis, Heliyon (2024)
50. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)